Literature DB >> 9416366

Natural history and spectrum of disease in adults with HIV/AIDS in Africa.

A D Grant1, G Djomand, K M De Cock.   

Abstract

Progression from seroconversion to the development of AIDS in Africa may be shorter than in industrialized countries, but there are insufficient data to be certain. Although the data are not always directly comparable, survival after an AIDS diagnosis appears to be substantially shorter in African countries and this may be partly because of later diagnosis of AIDS in Africa, but may also be because of environmental factors such as increased exposure to pathogens of high virulence and lack of access to care. Tuberculosis and bacterial infections are the most important causes of morbidity and mortality among hospitalized patients. Bacteraemia is frequent, particularly due to non-typhoid salmonellae and S. pneumoniae. Cryptosporidia and I. belli are the most frequently isolated pathogens in patients with diarrhoea; non-typhoid salmonellae and Shigella species are also commonly isolated when stool cultures are performed. Cerebral toxoplasmosis, and meningitis due to Cryptococcus, tuberculosis and bacterial pathogens are the most frequent neurological infections and cognitive changes are frequently identified when specifically looked for. Infections with atypical mycobacteria and Pneumocystis carinii are rare, as is CMV retinitis. In women, HIV infection is associated with cervical human papillomavirus and with SIL, although there is currently no evidence for an association with invasive cervical cancer. Individuals infected with HIV-2 progress to AIDS and to death more slowly than those infected with HIV-1, but seem to experience the same spectrum of opportunistic disease when they reach the stage of advanced disease. The limited data available suggest that HIV-infected individuals in Africa develop opportunistic disease at broadly the same level of immunosuppression as do individuals in industrialized countries, but death occurs at a higher range of CD4 counts, although still in the range consistent with advanced disease. Data are still lacking concerning the aetiology of common clinical presentations of HIV disease and the relative frequencies of specific opportunistic diseases in different regions, particularly from southern Africa. Tuberculosis is the single most important HIV-related opportunistic infection in African countries, but diagnosis, particularly of extrapulmonary disease, remains difficult. The lack of laboratory facilities makes the diagnosis of bacterial infections difficult in many parts of the continent and, since this situation is unlikely to change in the near future, clinical algorithms for syndromic management need to be evaluated. More information is needed about gynaecological disease in HIV-infected women. The most important research questions concern the development and evaluation of cost-effective regimes for prophylaxis and treatment of opportunistic disease in order to prolong healthy life in HIV-infected individuals.

Entities:  

Mesh:

Year:  1997        PMID: 9416366

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

Review 1.  African enigma: key player in human immunodeficiency virus pathogenesis in developing countries?

Authors:  M Clerici; S Declich; G Rizzardini
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.

Authors:  Salome Charalambous; Alison D Grant; Craig Innes; Christopher J Hoffmann; Rob Dowdeswell; Jan Pienaar; Katherine L Fielding; Gavin J Churchyard
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

Review 3.  HIV and tuberculosis coinfection: inextricably linked liaison.

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

4.  Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.

Authors:  S M Blower; K Koelle; D E Kirschner; J Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community.

Authors:  Keren Middelkoop; Linda-Gail Bekker; Landon Myer; Leigh F Johnson; Matthew Kloos; Carl Morrow; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

Review 6.  Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.

Authors:  C Sander; H McShane
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

7.  Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.

Authors:  Humphrey J Shao; John A Crump; Habib O Ramadhani; Leonard O Uiso; Sendui Ole-Nguyaine; Andrew M Moon; Rehema A Kiwera; Christopher W Woods; John F Shao; John A Bartlett; Nathan M Thielman
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

Review 8.  Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?

Authors:  Christoph G Lange; Ian J Woolley; Reinhard H Brodt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Clinical and ultrasonographic features of abdominal tuberculosis in HIV positive adults in Zambia.

Authors:  Edford Sinkala; Sylvia Gray; Isaac Zulu; Victor Mudenda; Lameck Zimba; Sten H Vermund; Francis Drobniewski; Paul Kelly
Journal:  BMC Infect Dis       Date:  2009-04-17       Impact factor: 3.090

10.  Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population.

Authors:  Shevin T Jacob; Christopher C Moore; Patrick Banura; Relana Pinkerton; David Meya; Pius Opendi; Steven J Reynolds; Nathan Kenya-Mugisha; Harriet Mayanja-Kizza; W Michael Scheld
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.